Gregory Gene Freitag

CIK 1492710 · General Counsel · last filed 2026-03-03

Gregory Gene Freitag is a General Counsel who has filed 68 SEC Form 4 insider transactions across 4 companies since 2010. The most recent filing, for PDSB, was dated Mar 3, 2026. Across all open-market trades the lifetime net is −$4.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $11.7M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$11.71M

Companies

4

Total Filings

68

Lifetime Open-Market Net

-$4.05M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PDSB Director 61,213 $0.69 $42.3K $75.0K 10 2026-03-03
ZyVersa Therapeutics, Inc. (ZVSA) Delisted Director $0.20 $0 2 2025-07-15
AXGN Director 283,498 $41.15 $11.67M -$4.12M 43 2024-06-06
PRESSURE BIOSCIENCES INC (PBIO) Delisted Director 1,422 $0 3 2011-10-07

Recent Filings

68 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-03-03 PDSB Grant (A) $0 EDGAR
2025-07-15 ZyVersa Therapeutics, Inc. (ZVSA) Delisted Grant (A) $0 EDGAR
2025-06-11 PDSB Grant (A) $0 EDGAR
2025-03-03 PDSB Buy (P) +15,060 $25.0K EDGAR
2024-08-13 AXGN Notice (144) −15,000 -$167.5K EDGAR
2024-07-18 ZyVersa Therapeutics, Inc. (ZVSA) Delisted Grant (A) $0 EDGAR
2024-06-25 PDSB Grant (A) $0 EDGAR
2024-06-06 AXGN Exer (M) +11,904 $0 EDGAR
2024-03-08 AXGN Sell (S) −25,000 -$225.0K EDGAR
2024-03-07 AXGN Notice (144) −25,000 -$225.0K EDGAR
Showing 110 of 68
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.